J.P. Morgan Notebook, Jan. 14: AbbVie, AstraZeneca, Juno & Bluebird

Day three of “The Pink Sheet” DAILY’s round-up of news and notes from the 2015 J.P. Morgan Healthcare Conference in San Francisco. Pricing remains center stage, with AbbVie weighing in on HCV and AstraZeneca’s Soriot predicting cost-competition in oncology. CAR-T continues to advance, with updates from Juno and bluebird.

While payer deals are becoming the name of the game in the newly competitive hepatitis C field, AbbVie Inc. Chief Financial Officer William Chase stressed during the firm’s breakout session at the J.P. Morgan Healthcare conference Jan. 14 that AbbVie is in a position to compete in the open market as well as with exclusive payer arrangements.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Clinical Trials

More from R&D